Related Experiment Video
Updated: Oct 3, 2025

Novel and Innovative Hybrid Technique for Type A Aortic Dissection
Published on: March 28, 2025
Effects of dexmedetomidine on surgery for type A acute aortic dissection outcome
Yu-Ting Cheng1, Kuang-Tso Lee2, Chih-Hsiang Chang3,4
1Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, Taoyuan City, Taiwan.
Insights
Postoperative dexmedetomidine infusion reduced severe acute kidney injury and dialysis needs in patients undergoing type A aortic dissection surgery. This is the first study to show dexmedetomidine
Area of Science:
- Cardiovascular Surgery
- Anesthesiology
- Nephrology
Background:
- Type A aortic dissection is a life-threatening condition requiring complex surgical intervention.
- Postoperative complications, including acute kidney injury (AKI), significantly impact patient outcomes.
- The role of dexmedetomidine in managing these patients remains largely uninvestigated.
Purpose of the Study:
- To evaluate the effect of postoperative dexmedetomidine infusion on clinical outcomes in patients who underwent surgery for acute type A aortic dissection.
- To assess the impact of dexmedetomidine on in-hospital mortality, composite outcomes, and specific renal complications.
Main Methods:
- Retrospective analysis of 511 patients undergoing acute type A aortic dissection surgery (January 2014 - December 2018) from the Chang Gung Research Database.
- One-to-two propensity score matching created comparable groups: 86 patients receiving postoperative dexmedetomidine and 158 not receiving it.
- Primary outcomes included in-hospital mortality and a composite of all-cause mortality, AKI, delirium, atrial fibrillation, and respiratory failure.
Main Results:
- No significant difference in in-hospital mortality or the composite outcome between the dexmedetomidine and non-dexmedetomidine groups.
- Significantly lower incidence of Acute Kidney Injury Network stage 3 AKI in the dexmedetomidine group (8.1% vs. 19.0%; OR, 0.38; p=0.020).
- Significantly lower risk of newly-onset dialysis in the dexmedetomidine group (4.7% vs. 13.3%; OR, 0.32; p=0.031).
Conclusions:
- Postoperative dexmedetomidine infusion significantly reduces the risk of severe acute kidney injury and the need for new dialysis in patients after type A aortic dissection surgery.
- Dexmedetomidine may offer a protective effect on renal function in this high-risk surgical population.
- This study provides the first evidence supporting the use of dexmedetomidine for mitigating AKI in type A aortic dissection patients.
Abstract:
No study has evaluated the effect of dexmedetomidine in patients who received surgery for type A aortic dissection. This is the first study to evaluate the effect of dexmedetomidine in aortic dissection patients. This study was executed using data from the Chang Gung Research Database in Taiwan. The CGRD contains the multi-institutional standardized electronic medical records from seven Chang Gung Memorial hospitals, the largest medical system in Taiwan. We retrospectively evaluate patients who received surgery for acute type A aortic dissection between January 2014 and December 2018. Overall, 511 patients were included, of whom 104 has received dexmedetomidine infusion in the postoperative period. One-to-two propensity score-matching yielded 86 cases in the dexmedetomidine group and 158 cases in the non-dexmedetomidine group. The in-hospital mortality and composite outcome including all-cause mortality, acute kidney injury, delirium, postoperative atrial fibrillation, and respiratory failure, were considered primary outcomes. The in-hospital mortality and composite outcome were similar between groups. The risk of Acute Kidney Injury Network stage 3 acute kidney injury was significantly lower in the dexmedetomidine group than in the non-dexmedetomidine group (8.1% vs 19.0%; OR, 0.38; 95% CI, 0.17-0.86; p = 0.020. The risk of newly-onset dialysis was also significantly lower in the dexmedetomidine group than in the non-dexmedetomidine group (4.7% vs 13.3%; OR, 0.32; 95% CI, 0.11-0.90; p = 0.031). Post-operative dexmedetomidine infusion significantly reduced the rate of severe acute kidney injury and newly-onset dialysis in patients who received surgery for acute type A aortic dissection.
Related Concept Videos
Aneurysm IV: Nursing Management
Depolarizing Blockers: Pharmocokinetics
Parenteral Anesthetics: Overview
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
General Anesthesia: Overview
General anesthesia induces unconsciousness in the whole body, while the others target specific areas or sensations. It is administered to minimize adverse effects, maintain...
Cardiomyopathy VII: Pre and Post Operative Nursing Management

